This Incredibly Cheap Growth Stock Could Soar 44%, According to Wall Street Analysts
Opera delivered outstanding results recently and its guidance points toward an improvement in its growth.
The stock is cheaply valued, and its earnings growth suggests it is on track to deliver solid gains to investors.
10 stocks we like better than Opera ›
Shares of Opera (NASDAQ: OPRA) have blown hot and cold on the market so far this year, as the company's strong quarterly results have been overshadowed by the broader stock market weakness; however, analysts are expecting shares of the Norway-based web browser maker to reverse the 8% drop they have witnessed so far in 2025 and head higher in the coming year.
Opera stock carries a 12-month price target of $25 as per the seven analysts covering the stock, with all of them having a buy rating. That points toward 44% gains from current levels. There is a good chance that Opera will be able to indeed deliver such solid gains and head higher thanks to its impressive growth and attractive valuation.
Let's look at the reasons why buying Opera stock right now could turn out to be a smart move.
Opera released its first-quarter results on April 28, and the company crushed Wall Street's expectations by a big margin. Its revenue shot up 40% year over year, while adjusted earnings increased by 35%. This marks a significant improvement from the year-ago period when the company reported a 17% jump in revenue and a flat bottom-line performance.
What's more, Opera has raised its full-year revenue growth guidance by three points to 20% to $575 million at the midpoint. The company, which is known for its web and mobile browsers, has been benefiting from the stronger monetization of its properties. Advertisers are now spending more money on the company's Opera Ads platform, which gives them multiple channels to reach its 293 million monthly active users (MAUs) across both mobile and desktop.
From programmatic advertising that uses real-time data to help advertisers buy and serve ads to premium display areas on its web browsers to push notifications and in-app notifications, Opera is trying to entice advertisers by offering multiple ways to display ads. The good part is that this strategy is paying off. Opera's ad revenue shot up an impressive 63% year over year in the previous quarter and accounted for two-thirds of its top line.
Another thing worth noting is that Opera's average revenue per user (ARPU) increased by an impressive 45% year over year in Q1, owing to the terrific growth of the advertising business. Looking ahead, there is a good chance that Opera will be able to win a bigger share of advertisers' wallets as it is integrating agentic artificial intelligence (AI) into its browsers that will perform tasks on users' behalf.
Opera's Browser Operator platform will allow users to shop online, book tickets, look for hotels, and complete other tasks on the web with the help of an AI agent that will take instructions from users before going about its job. This could help Opera strike more advertising deals through preferred partnerships and revenue-sharing models. For instance, the AI agent could direct the user toward a preferred travel booking website for booking tickets or hotels, and Opera could earn a commission out of the transaction.
All this explains why the company is now confident of delivering stronger growth in 2025. Even better, analysts are expecting Opera to maintain a healthy double-digit growth rate for the next couple of years as well.
Consensus estimates are projecting an 18% increase in Opera's earnings this year to $1.14 per share. That's expected to accelerate to 23% next year, which is not surprising considering the stellar improvement in the ARPU that the company clocked last quarter.
With Opera integrating new features, such as AI, into its browsers that could unlock more value for advertisers and encourage them to spend more on its platform, it won't be surprising to see the company's earnings growth accelerating beyond the next couple of years. That's why now would be a good time to buy this tech stock as it is trading at just 18.5 times earnings, a discount to the Nasdaq-100 index's earnings multiple of 31 (using the index as a proxy for tech stocks).
If the market decides to put a higher valuation on Opera because of its improving growth profile and it trades in line with the index's multiple after a year, its stock price could hit $35 (based on the projected earnings estimate for 2025). That would be nearly double the current levels, indicating that Opera has the potential to outpace analysts' one-year price target and skyrocket substantially going forward.
Before you buy stock in Opera, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Opera wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!*
Now, it's worth noting Stock Advisor's total average return is 978% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
This Incredibly Cheap Growth Stock Could Soar 44%, According to Wall Street Analysts was originally published by The Motley Fool
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving elraglusib/GnP Risk of death was reduced by 37% (HR=0.63) in patients treated with elraglusib/GnP Data featured as an oral presentation at the ASCO Annual Meeting Company plans to engage with FDA in the second half of 2025 to align on a path towards product registration Company to host KOL event today at 6:30 pm CDT to discuss 1801 Part 3B results CHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ('Actuate' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today presented topline results from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of Clinical Oncology (ASCO) Annual Meeting. Abstract Title: Preliminary results from the randomized phase 2 study (1801 Part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).Abstract Number: 4006Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryPresenter: Devalingam Mahalingam, MD, PhDOral Presentation Date and Time: Saturday, May 31, 2025, 4:48 PM CDT The trial met its primary endpoint of improved median overall survival. Median overall survival (mOS) increased by almost three months (10.1 months vs 7.2 months, HR=0.63, log-rank p=0.01) with a 37% reduction in the risk of death and strong statistical significance, representing a clinically meaningful advance in the potential treatment of mPDAC. Patients receiving elraglusib with GnP achieved a 12-month survival rate in 44.1% of patients treated—double that of GnP alone (22.3%). Dr. Deva Mahalingam, MD, PhD, Northwestern University Feinberg School of Medicine, and lead principal investigator of the 1801 Part 3B trial commented, 'Pancreatic cancer continues to represent one of the highest unmet medical needs with no major treatment advances in recent years, bar some molecular targets in small subsets of patients. New mechanisms of action are urgently needed. The addition of elraglusib to the existing chemotherapy backbone of gemcitabine and nab-paclitaxel is promising and may represent a meaningful therapeutic advance for patients with pancreatic cancer.' Daniel Schmitt, President & Chief Executive Officer of Actuate added, 'We significantly improved mOS, cut the risk of death by 37%, and doubled the 12-month survival rate. Combined with a manageable safety profile and strong emerging mechanistic insights, these results reinforce the transformative potential of our GSK-3β inhibitor program. Based on the clear clinical benefit and well-tolerated safety profile, we intend to engage with the FDA and EMA in the second half of this year to align on a path to registration. We believe this enables us to move rapidly towards commercialization and delivery of this first-in-class therapy to patients with an urgent unmet need.' Efficacy Figure 1 below depicts the Kaplan-Meier estimate for mOS (10.1 months vs 7.2 months, HR=0.63, log-rank p=0.01) with a 37% reduction in the risk of death, displaying a clear clinical survival benefit for patients treated in the elraglusib/GnP combination arm vs GnP alone arm. Actuate-1801 Part 3B: Kaplan-Meier Estimate for mOS as of March 27, 2025 (Topline data cut-off).In addition to the improved mOS and one-year survival rate, a continued survival benefit was also observed at eighteen and twenty-four months (survival rates of 19.7% vs 4.4% and 13.8% vs 0% in the elraglusib/GnP combination arm vs the GnP arm, respectively). The elraglusib/GnP combination treatment also resulted in numerically improved overall response rates (29.0% in the elraglusib/GnP combination arm vs 21.8% in the GnP arm) and improvements in median progression-free survival and median duration of response of 5.6 months vs 5.1 months, and 5.5 months vs 4.0 months in the elraglusib/GnP combination arms vs GnP arms, respectively. Safety and Biomarker Findings The trial also met its primary safety endpoint. Treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs) in the elraglusib/GnP combination arm were similar to those observed in the GnP arm, indicating a favorable risk-benefit profile for the elraglusib/GnP combination. Treatment-related adverse events (TRAEs) were mostly Grade 1-2, with the most frequent TRAEs observed (in about two-thirds of patients) being transient visual impairments that were reversible and non-progressive While Grade 3 or higher neutropenia was observed, similar rates of febrile neutropenia and sepsis were observed in both treatment arms. Pre-dose cytokine analysis that suggested lower baseline levels of key immune modulators, including CCL3, IL-1α, IL-18, TGF-β, and TRAIL R3, were correlated with improved 1-year survival. Increased CD8-positive and granzyme B-positive T cells, increased NK cells, and decreased myeloid-derived suppressor cells were observed in tumor biopsies only from elraglusib-treated patients. This exploratory result confirms elraglusib proposed immune modulating mechanism of action in patients with mPDAC. KOL Event Actuate will host a KOL event for the investment community today, May 31, 2025, at 6:30 PM CDT to review the data. The webinar will feature a fireside discussion moderated by Daniel Schmitt, President & Chief Executive Officer of Actuate, and will include four distinguished KOLs: Tanios Bekaii-Saab, MD, FACP, Mayo Clinic College of Medicine and Science; Devalingam Mahalingam, MD, Northwestern University Feinberg School of Medicine; Rachna Shroff, MD, MS, FASCO, University of Arizona Cancer Center; and Colin Weekes, MD, PhD, Massachusetts General Hospital. Event Details: Date and Time: Saturday, May 31, 2025, at 6:30 pm CDT Format: In-person and via live webcast Registration: Click here A replay of the event will be available on the Investor Relations section of the Actuate website. About Actuate-1801 Part 3B Study The Actuate-1801 Part 3B study (NCT03678883) is a randomized, controlled Phase 2 trial of elraglusib with GnP versus GnP alone in first-line mPDAC. The trial enrolled 286 mPDAC patients with no prior systemic treatment for metastatic disease, who were randomized 2:1 to the elraglusib treatment arm (elraglusib + GnP) or the control arm (GnP alone). Elraglusib is administered at a dose of 9.3 mg/kg by IV infusion on Day 1 of each week of a 28-day cycle. The primary endpoint for this study is median overall survival, with OS summarized throughout the study by estimates of 1-year survival. Secondary endpoints are DCR, ORR, PFS, and of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity, and regulation of gene expression, leading to alterations in tumor metabolism and Epithelial-to-Mesenchymal Transition (EMT). About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function. For additional information, please visit the Company's website at Forward-Looking Statements This press release contains forward-looking statements about us, including our and other parties' clinical trials and development plans, and our industry. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities and within the medical community; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve positive clinical results or favorable preclinical results, and we may not be able to make regulatory submissions or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2025, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading 'Item 1A. Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 15, 2025, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. Investor ContactMike MoyerManaging DirectorLifeSci Advisors, LLCmmoyer@ A photo accompanying this announcement is available at
Yahoo
an hour ago
- Yahoo
Former tenant wins suit against Fredericton property manager but still waits for payment
A New Brunswick tenant recently sued his former property manager over a promise of internet services that were never provided — and he won. But Matthew Habermacher took a less conventional route to address his apartment complaint — small claims court. And even though the court sided with Habermacher, the property manager has his own ideas about paying him. In New Brunswick, a tenant concerned about issues such as a withheld security deposit or a rent increase can ask the Residential Tenancies Tribunal to review the issue. But some tenants have reported cases of retribution in the past after making complaints to the tribunal. Fear of such a reaction from his property manager was on Habermacher's mind as well. Habermacher, now based in Moncton, moved to Fredericton in June 2023 after law school for a year-long clerkship at the Fredericton courthouse. At his new apartment, one of the terms of tenancy was that cable and internet services were included. But when he did the walk-through of the Brunswick Street apartment, he didn't see a router. "I figured it must be for the whole building," Habermacher said. "There are four apartments in that building, and [I] asked that the landlord's agent would let me know when he gets back to the office what the … network name and password are. "So he got back to his office, and he wrote back to let me know that it was not going to be included, even though it was included in the rental agreement." The building that Habermacher was living in was managed by Hanwell-based Dooryard Property Management Inc. Led by Matthew Hunter, the company manages buildings for property owners and takes on landlord tasks such as finding and screening tenants, handling rent payments, maintaining the property and dealing with tenant issues. Hunter said it was the company's first time listing the property Habermacher leased, and it was simply a mistake the listing said the internet was included. Habermacher said the company offered $200, or to take that amount off the next month's rent, in lieu of internet services. But he said he rejected the offer because it wouldn't cover a year's worth of internet. He considered complaining to the Residential Tenancies Tribunal during his tenancy, but he worried this could create a bad relationship with the property manager. "Or do I wait until the end of the year, when I know exactly what my losses are, and then ask to be refunded then, which is what I ultimately decided to do," Habermacher said. WATCH | Matthew Habermacher describes how he sued property manager: While Habermacher never accepted the $200 offer, Hunter said he didn't expect any issues because Dooryard didn't hear anything again about the internet. "[He] moved out without incident, gave proper notice, you know, everything a tenant should," Hunter said. "Once we signed over the security deposit … he's like, 'Oh, by the way, you owe me $1,000 and change.'" Hunter said he tried to explain again that the internet promise was a mistake. Habermacher filed a claim with small claims court in July 2024, and the hearing happened in January 2025. He said the hearing officer had to first confirm the court had jurisdiction because normally, the tenancies tribunal handles rental cases. "She had presented us with decisions where the Residential Tenancies Tribunal had made a decision about the deposit, and the small claims court had decided not to interfere with it," Habermacher said. "In my case, there was no decision from the Residential Tenancies Tribunal, and as soon as my lease was done, they lost jurisdiction." Hunter said he believes the matter should have gone to the tribunal instead of small claims. The court ultimately found Habermacher was entitled to the full $1,509.01, which includes what he paid for internet services and $500 in legal fees. When Habermacher contacted Hunter after the decision, Hunter sought a break and asked if he could pay in $100 monthly instalments. Habermacher wanted full payment by April 29, but after more emails, the two agreed on a payment schedule of $100 a month. Habermacher did not agree to Hunter's condition request that he not be penalized if payment wasn't made on the first business day of every month. Hunter said he's willing to pay Habermacher if his condition is accepted. "We're a property management company — the busiest day of the month for us is the first," said Hunter, who wanted "in writing that I get a few days grace." After more emails, Habermacher eventually wrote that he planned to have the decision registered with the sheriff if the money wasn't paid in full or two lump sums. "I'm not comfortable with having conditions imposed on me when this is a court judgment," Habermacher said in the interview. Habermacher said, as a criminal law lawyer, having some legal knowledge helped with understanding what to do in this situation, but the civil system was unfamiliar territory. And he said he's even more unfamiliar with having a judgment registered and enforced, which he said is his next step. He said the whole process has been "very difficult." "There's a lot of steps to jump through, and I can understand why someone would abandon it or decide not to collect." CBC is not responsible for third-party content.
Yahoo
an hour ago
- Yahoo
Google says to appeal online search antitrust ruling
Google said Saturday it will appeal a ruling against it for anti-competitive practices in online search, a day after urging a US judge to reject the suggestion it spin off its Chrome browser. "We will wait for the Court's opinion. And we still strongly believe the Court's original decision was wrong, and look forward to our eventual appeal," the tech giant wrote on X. Google was found guilty in the summer of 2024 of illegal practices to establish and maintain its monopoly in online search by a federal judge in Washington. The Justice Department is now demanding remedies that could transform the digital landscape: Google's divestiture from its Chrome browser and a ban on entering exclusivity agreements with smartphone manufacturers to install the search engine by default. It is also asking that the California-based company be forced to share the data used to produce search results on Chrome. The department's proposal "reserves the right for the government to decide who gets Google users' data. Not the Court," Google said Saturday. "While we heard a lot about how the remedies would help various well-funded competitors (w/ repeated references to Bing), we heard very little about how all this helps consumers," Google added, referring to the Microsoft-owned search engine. The firm has proposed much more limited measures, including giving phone manufacturers the possibility to pre-install its Google Play app store but not Chrome or the search engine. The Friday hearing devoted to arguments marked the end of the trial to determine Google's penalty. The judge's decision is expected by August. juj/vla/bjt/mlm
